AR was shown to facilitate glutamine-dependent cisplatin resistance in chondrosarcoma, whereas NADPH oxidase inhibitors were shown to antagonize cisplatin-induced cell death in SW1353, JJ012 and SW1353-R-AR shRNA cells. This evidence concerns the gene FMO5 and chondrosarcoma.